Micrus Receives FDA Approval for Intracranial Stent Clinical Trial

Micrus Endovascular Corporation announced that the Vitesse Intracranial Stent Study for Ischemic Therapy (VISSIT) clinical trial application has been conditionally approved by the U.S. Food and Drug Administration (FDA).
CentreDaily.com